249 related articles for article (PubMed ID: 29803930)
21. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
Galvin JE
Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
[TBL] [Abstract][Full Text] [Related]
22. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
23. Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson's Disease.
Vivacqua G; Latorre A; Suppa A; Nardi M; Pietracupa S; Mancinelli R; Fabbrini G; Colosimo C; Gaudio E; Berardelli A
PLoS One; 2016; 11(3):e0151156. PubMed ID: 27011009
[TBL] [Abstract][Full Text] [Related]
24. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA expressing profiles in A53T mutant alpha-synuclein transgenic mice and Parkinsonian.
Mo M; Xiao Y; Huang S; Cen L; Chen X; Zhang L; Luo Q; Li S; Yang X; Lin X; Xu P
Oncotarget; 2017 Jan; 8(1):15-28. PubMed ID: 27965467
[TBL] [Abstract][Full Text] [Related]
26. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
27. [Proteomic biomarkers in Parkinson's disease].
Bandrés S; Durán R; Barrero F; Ramírez M; Vives F
Rev Neurol; 2014 Feb; 58(4):166-74. PubMed ID: 24504879
[TBL] [Abstract][Full Text] [Related]
28. Autophagic- and Lysosomal-Related Biomarkers for Parkinson's Disease: Lights and Shadows.
Xicoy H; Peñuelas N; Vila M; Laguna A
Cells; 2019 Oct; 8(11):. PubMed ID: 31731485
[TBL] [Abstract][Full Text] [Related]
29. Alpha-synuclein and Parkinson's disease: a proteomic view.
Fasano M; Lopiano L
Expert Rev Proteomics; 2008 Apr; 5(2):239-48. PubMed ID: 18466054
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
31. α-Synuclein in the colon and premotor markers of Parkinson disease in neurologically normal subjects.
Kim JS; Park IS; Park HE; Kim SY; Yun JA; Jung CK; Sung HY; Lee JK; Kang WK
Neurol Sci; 2017 Jan; 38(1):171-179. PubMed ID: 27803984
[TBL] [Abstract][Full Text] [Related]
32. Dysregulated microRNAs in neural system: Implication in pathogenesis and biomarker development in Parkinson's disease.
Lu J; Xu Y; Quan Z; Chen Z; Sun Z; Qing H
Neuroscience; 2017 Dec; 365():70-82. PubMed ID: 28964753
[TBL] [Abstract][Full Text] [Related]
33. Establishing a framework for neuropathological correlates and glymphatic system functioning in Parkinson's disease.
Sundaram S; Hughes RL; Peterson E; Müller-Oehring EM; Brontë-Stewart HM; Poston KL; Faerman A; Bhowmick C; Schulte T
Neurosci Biobehav Rev; 2019 Aug; 103():305-315. PubMed ID: 31132378
[TBL] [Abstract][Full Text] [Related]
34. Higher nigrostriatal dopamine neuron loss in early than late onset Parkinson's disease?--a [99mTc]-TRODAT-1 SPECT study.
Shih MC; Franco de Andrade LA; Amaro E; Felicio AC; Ferraz HB; Wagner J; Hoexter MQ; Lin LF; Fu YK; Mari JJ; Tufik S; Bressan RA
Mov Disord; 2007 Apr; 22(6):863-6. PubMed ID: 17290452
[TBL] [Abstract][Full Text] [Related]
35. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
[TBL] [Abstract][Full Text] [Related]
36. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease.
Shannon KM; Keshavarzian A; Mutlu E; Dodiya HB; Daian D; Jaglin JA; Kordower JH
Mov Disord; 2012 May; 27(6):709-15. PubMed ID: 21766334
[TBL] [Abstract][Full Text] [Related]
37. MicroRNAs in Parkinson's disease.
Singh A; Sen D
Exp Brain Res; 2017 Aug; 235(8):2359-2374. PubMed ID: 28526930
[TBL] [Abstract][Full Text] [Related]
38. Low levels of astroglial markers in Parkinson's disease: relationship to α-synuclein accumulation.
Tong J; Ang LC; Williams B; Furukawa Y; Fitzmaurice P; Guttman M; Boileau I; Hornykiewicz O; Kish SJ
Neurobiol Dis; 2015 Oct; 82():243-253. PubMed ID: 26102022
[TBL] [Abstract][Full Text] [Related]
39. Patterns of striatal functional connectivity differ in early and late onset Parkinson's disease.
Hou Y; Yang J; Luo C; Ou R; Song W; Liu W; Gong Q; Shang H
J Neurol; 2016 Oct; 263(10):1993-2003. PubMed ID: 27394147
[TBL] [Abstract][Full Text] [Related]
40. The regulatory role of α-synuclein and parkin in neuronal cell apoptosis; possible implications for the pathogenesis of Parkinson's disease.
Yasuda T; Mochizuki H
Apoptosis; 2010 Nov; 15(11):1312-21. PubMed ID: 20221696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
